65.06
price down icon1.48%   -0.98
after-market 시간 외 거래: 65.06
loading
전일 마감가:
$66.04
열려 있는:
$65.71
하루 거래량:
3.74M
Relative Volume:
1.92
시가총액:
$12.59B
수익:
$4.41B
순이익/손실:
$21.27M
주가수익비율:
203.31
EPS:
0.32
순현금흐름:
$288.81M
1주 성능:
+1.27%
1개월 성능:
+7.66%
6개월 성능:
-12.78%
1년 성능:
+13.54%
1일 변동 폭
Value
$63.93
$65.77
1주일 범위
Value
$63.93
$66.26
52주 변동 폭
Value
$53.56
$83.95

인사이트 코퍼레이션 Stock (INCY) Company Profile

Name
명칭
Incyte Corp
Name
전화
(302) 498-6700
Name
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
직원
2,617
Name
트위터
@Incyte
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
INCY's Discussions on Twitter

INCY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INCY
Incyte Corp
65.06 12.44B 4.41B 21.27M 288.81M 0.32
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-18 다운그레이드 Guggenheim Buy → Neutral
2025-03-18 다운그레이드 William Blair Outperform → Mkt Perform
2024-12-17 개시 UBS Neutral
2024-10-29 업그레이드 BofA Securities Neutral → Buy
2024-10-01 개시 Wolfe Research Outperform
2024-09-18 다운그레이드 Truist Buy → Hold
2024-07-02 다운그레이드 BMO Capital Markets Market Perform → Underperform
2024-05-23 개시 Deutsche Bank Hold
2024-04-23 개시 Cantor Fitzgerald Neutral
2024-02-23 개시 Jefferies Buy
2024-02-14 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 업그레이드 Leerink Partners Market Perform → Outperform
2023-12-04 업그레이드 Guggenheim Neutral → Buy
2023-11-21 다운그레이드 Goldman Buy → Neutral
2023-07-25 개시 Citigroup Buy
2023-05-04 다운그레이드 BofA Securities Buy → Neutral
2023-04-10 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-03-24 업그레이드 SVB Securities Underperform → Market Perform
2023-01-31 개시 Piper Sandler Overweight
2022-08-03 다운그레이드 Evercore ISI Outperform → In-line
2022-08-03 다운그레이드 Guggenheim Buy → Neutral
2022-07-28 개시 Wells Fargo Equal Weight
2022-02-09 다운그레이드 SVB Leerink Mkt Perform → Underperform
2022-01-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-19 개시 BMO Capital Markets Market Perform
2021-07-20 업그레이드 The Benchmark Company Hold → Buy
2021-02-10 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-01-07 개시 Truist Buy
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-06-16 개시 The Benchmark Company Hold
2020-05-06 다운그레이드 JP Morgan Overweight → Neutral
2020-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-24 재개 William Blair Outperform
2020-03-13 업그레이드 BofA/Merrill Neutral → Buy
2020-02-04 재개 BofA/Merrill Neutral
2020-01-03 재확인 BMO Capital Markets Market Perform
2020-01-03 다운그레이드 Mizuho Buy → Neutral
2020-01-02 다운그레이드 Guggenheim Buy → Neutral
2019-10-03 개시 Mizuho Buy
2019-09-12 개시 BMO Capital Markets Market Perform
2019-09-05 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 재개 Morgan Stanley Equal-Weight
2019-09-05 업그레이드 Oppenheimer Perform → Outperform
2019-05-21 개시 Credit Suisse Neutral
2019-05-03 다운그레이드 Barclays Overweight → Equal Weight
2019-04-11 개시 Stifel Hold
2019-04-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-01-24 업그레이드 William Blair Mkt Perform → Outperform
모두보기

인사이트 코퍼레이션 주식(INCY)의 최신 뉴스

pulisher
May 30, 2025

SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha

May 30, 2025
pulisher
May 29, 2025

Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report? - Yahoo Finance

May 29, 2025
pulisher
May 28, 2025

Vitiligo Market Growth Trends and Forecast Report 2025-2033Rising Awareness, Diagnostic Advances, Innovative Therapies, and Expanding Global Healthcare Access - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Incyte (NASDAQ:INCY) Price Target Raised to $73.00 at Truist Financial - Defense World

May 28, 2025
pulisher
May 27, 2025

Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential - Investing.com

May 27, 2025
pulisher
May 27, 2025

Incyte’s SWOT analysis: stock faces patent cliff amid pipeline potential By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Incyte to Present at Upcoming Investor Conference on Monday, June 9, 2025 at 11:20 am (ET) - BioSpace

May 27, 2025
pulisher
May 27, 2025

Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.

May 27, 2025
pulisher
May 27, 2025

Incyte (INCY) Target Price Raised by Truist Securities | INCY St - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Incyte (INCY) Sees Price Target Boost from Truist Analyst | INCY Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Incyte to Present at Upcoming Investor Conference - Business Wire

May 27, 2025
pulisher
May 24, 2025

Incyte Co. (NASDAQ:INCY) Shares Bought by Cetera Investment Advisers - Defense World

May 24, 2025
pulisher
May 22, 2025

3 Reasons INCY is Risky and 1 Stock to Buy Instead - Yahoo Finance

May 22, 2025
pulisher
May 19, 2025

FDA approves Incyte’s retifanlimab combo for SCAC treatment - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

Is Wall Street Bullish or Bearish on Incyte Stock? - inkl

May 19, 2025
pulisher
May 19, 2025

Is Wall Street Bullish Or Bearish On Incyte Stock? - Barchart.com

May 19, 2025
pulisher
May 17, 2025

Incyte Gets FDA Approval for Zynyz in New Cancer Indication - MSN

May 17, 2025
pulisher
May 16, 2025

Incyte adds more FDA approvals for Zynyz in cancer - BioWorld MedTech

May 16, 2025
pulisher
May 16, 2025

FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Trea - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Incyte granted FDA approval of Zynyz for SCAC - The Pharma Letter

May 16, 2025
pulisher
May 16, 2025

Incyte’s PD-1 Blocker Wins First-Line Anal Cancer Approval - BioSpace

May 16, 2025
pulisher
May 15, 2025

No Article III Appellate Standing Under the Sun - Lexology

May 15, 2025
pulisher
May 15, 2025

FDA Broadens Approval for Incyte's Zynyz in Cancer Treatments (I - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FDA Approves Incyte's (INCY) Zynyz for Advanced Anal Cancer Treatment | INCY Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States | INCY Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FDA approves new anal cancer treatment Zynyz by Incyte - Investing.com

May 15, 2025
pulisher
May 15, 2025

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States – Company AnnouncementFT.com - Financial Times

May 15, 2025
pulisher
May 15, 2025

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - The Joplin Globe

May 15, 2025
pulisher
May 14, 2025

Pharma Company Incyte Settles Novartis Royalties Dispute for $280 Million, SEC Records Show - Law.com

May 14, 2025
pulisher
May 14, 2025

Incyte Corporation (INCY) Reaches Settlement with Novartis Over Royalty Dispute - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Incyte (INCY) Reaches $280M Settlement with Novartis Over Jakafi Royalties - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com

May 14, 2025
pulisher
May 14, 2025

Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com

May 14, 2025
pulisher
May 14, 2025

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Incyte settles royalty dispute with Novartis for $280 million - Investing.com

May 14, 2025
pulisher
May 13, 2025

Incyte at Bank of America Conference: Strategic Insights on Growth - Investing.com

May 13, 2025
pulisher
May 13, 2025

Incyte To Present At 2025 BofA Securities Health Care Conference; Webcast At 4:40 PM ET - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Latest Federal Court Cases: Pharmaceutical Patent Protections - JD Supra

May 13, 2025
pulisher
May 13, 2025

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

Incyte Corporation: Here Are The 5 Major Factors Propelling Our ‘Outperform’ Rating! - Smartkarma

May 12, 2025
pulisher
May 12, 2025

Steroid Refactory Acute Graft-Versus-Host Disease Market Set - openPR.com

May 12, 2025
pulisher
May 11, 2025

Incyte Co. (NASDAQ:INCY) Holdings Raised by Stifel Financial Corp - Defense World

May 11, 2025
pulisher
May 11, 2025

Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN

May 11, 2025
pulisher
May 09, 2025

New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News

May 09, 2025
pulisher
May 09, 2025

Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech

May 09, 2025
pulisher
May 08, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace

May 08, 2025
pulisher
May 07, 2025

Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360

May 07, 2025
pulisher
May 07, 2025

US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News

May 07, 2025
pulisher
May 05, 2025

Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com

May 05, 2025

인사이트 코퍼레이션 (INCY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):